EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immune attack on tough cancers: can a combo drug beat the odds?
Disease control OngoingThis study is testing whether adding a new immunotherapy drug (varlilumab) to an existing one (nivolumab) works better than nivolumab alone for patients with aggressive B-cell lymphomas that have come back or stopped responding to standard treatments. The goal is to see if the tw…
Matched conditions: EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for Hard-to-Treat cancers: adding a pill to standard chemo
Disease control OngoingThis study is testing if adding a pill called venetoclax to standard chemotherapy works better than chemotherapy alone for people with aggressive types of B-cell lymphoma. The goal is to better control the cancer and keep it from coming back. About 363 adults with specific, hard-…
Matched conditions: EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New pill aims to boost cancer fight for seniors
Disease control TerminatedThis study is for people aged 75 and older who have just been diagnosed with certain aggressive types of lymphoma. It compares the current standard treatment (a combination of drugs called R-miniCHOP) to that same treatment plus a new oral drug called CC-486. The main goals are t…
Matched conditions: EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC